Barclays Maintains Equal-Weight on Gates Industrial Corp, Lowers Price Target to $14
Barclays analyst Julian Mitchell maintains Gates Industrial Corp (NYSE:GTES) with a Equal-Weight and lowers the price target from $15 to $14.
RBC Capital Downgrades Gates Industrial Corp to Sector Perform, Lowers Price Target to $14
RBC Capital analyst Deane Dray downgrades Gates Industrial Corp (NYSE:GTES) from Outperform to Sector Perform and lowers the price target from $17 to $14.
6 Analysts Have This to Say About Gates Industrial Corp
Within the last quarter, Gates Industrial Corp (NYSE:GTES) has observed the following analyst ratings:
Morgan Stanley Maintains Equal-Weight on Gates Industrial Corp, Lowers Price Target to $13
Morgan Stanley analyst Joshua Pokrzywinski maintains Gates Industrial Corp (NYSE:GTES) with a Equal-Weight and lowers the price target from $15 to $13.
Keybanc Maintains Overweight on Gates Industrial Corp, Lowers Price Target to $18
Keybanc analyst Jeffrey Hammond maintains Gates Industrial Corp (NYSE:GTES) with a Overweight and lowers the price target from $20 to $18.
Gates Industrial Corp Q1 Adj. EPS $0.26 Beats $0.22 Estimate, Sales $893.40M Beat $871.17M Estimate
Gates Industrial Corp (NYSE:GTES) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.22 by 18.18 percent. This is a 21.21 percent decrease over earnings of $0.33 per share from
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
